Neoplastic meningitis from solid tumors: a prospective clinical study in lombardia and a literature review on therapeutic approaches
- PMID: 23401780
- PMCID: PMC3562687
- DOI: 10.1155/2013/147325
Neoplastic meningitis from solid tumors: a prospective clinical study in lombardia and a literature review on therapeutic approaches
Abstract
Neoplastic dissemination to the leptomeninges is an increasingly common occurrence in patients with both haematological and solid tumors arising outside the central nervous system. Both refinement of diagnostic techniques (Magnetic resonance imaging) and increased survival in patients treated with targeted therapies for systemic tumors account for this increased frequency. Cerebrospinal fluid cytological analysis and MRI confirm clinical diagnosis based on multifocal central nervous system signs/symptoms in a patient with known malignancy. Overall survival in patients with leptomeningeal neoplastic dissemination from solid tumors is short, rarely exceeding 3-4 months. However, selected patients may benefit from aggressive therapies, Apart from symptomatic treatment, intrathecal chemotherapy is used, with both free (methotrexate, Thiotepa, AraC) and liposomal antitumor agents (liposomal AraC). Palliative radiotherapy is indicated only in cases of symptomatic bulky disease, surgery is limited to positioning of Ommaya recervoirs or C5F shunting. We report clinical data on a cohort of 26 prospectively followed patients with neoplastic leptomeningitis followed in Lombardia, Italy, in 2011. Prognostic factors and pattern of care are reported.
Figures



Similar articles
-
Neoplastic meningitis.Curr Treat Options Oncol. 2001 Dec;2(6):517-27. doi: 10.1007/s11864-001-0073-x. Curr Treat Options Oncol. 2001. PMID: 12057097 Review.
-
Leptomeningeal neoplasms.Curr Treat Options Neurol. 2007 Jul;9(4):283-93. doi: 10.1007/s11940-007-0014-5. Curr Treat Options Neurol. 2007. PMID: 17580008
-
Novel Therapeutic Approaches in Neoplastic Meningitis.Cancers (Basel). 2022 Dec 25;15(1):119. doi: 10.3390/cancers15010119. Cancers (Basel). 2022. PMID: 36612116 Free PMC article. Review.
-
Therapy of leptomeningeal metastasis in solid tumors.Cancer Treat Rev. 2016 Feb;43:83-91. doi: 10.1016/j.ctrv.2015.12.004. Epub 2015 Dec 24. Cancer Treat Rev. 2016. PMID: 26827696 Review.
-
Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours.Lancet Oncol. 2010 Sep;11(9):871-9. doi: 10.1016/S1470-2045(10)70034-6. Epub 2010 Jul 2. Lancet Oncol. 2010. PMID: 20598636 Review.
Cited by
-
Autocrine GMCSF Signaling Contributes to Growth of HER2+ Breast Leptomeningeal Carcinomatosis.Cancer Res. 2021 Sep 15;81(18):4723-4735. doi: 10.1158/0008-5472.CAN-21-0259. Epub 2021 Jul 9. Cancer Res. 2021. PMID: 34247146 Free PMC article.
-
Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience.Neurol Sci. 2013 Dec;34(12):2151-7. doi: 10.1007/s10072-013-1358-0. Epub 2013 Mar 24. Neurol Sci. 2013. PMID: 23525755
References
-
- Gleissner B, Chamberlain MC. Neoplastic meningitis. The Lancet Neurology. 2006;5(5):443–452. - PubMed
-
- Kesari S, Batchelor TT. Leptomeningeal metastases. Neurologic Clinics. 2003;21(1):25–66. - PubMed
-
- DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. Journal of Neuro-Oncology. 1998;38(2-3):245–252. - PubMed
-
- Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49(4):759–772. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources